What do the new ESC Guidelines for the treatment of heart failure bring to internists?
Authors:
Jindřich Špinar; Lenka Špinarová; Jiří Vítovec
Authors‘ workplace:
I. interní kardioangiologická klinika FN USA a LF MU, Brno
Published in:
Vnitř Lék 2022; 68(2): 104-110
Category:
Review Articles
Overview
Chronic heart failure is in european countries in 0,4–2,0% population with an increase with age. The improved care of acute cases enables to decrease the number of patients with chronic heart failure.The disease has a bad prognosis, the diagnosis therapy are demanding. European guidelines for diagnosis and treatment heart failure stress, that patients should have all 4 drugs with class 1 reccomendation (ACE‑ I/ARNI, betablockers, MRA and SGLT2) in reccomended doses. These drugs will be given step by step with dose titration.
Keywords:
diagnosis – treatment – chronic heart failure
Sources
1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European heart journal. 2021;00:1-128. doi: 101093/eurheartj/ehab 368.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
![Issue 2](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/5806d994e7db229d69c471b6a69ab7ac.jpg)
2022 Issue 2
Most read in this issue
- Oral semaglutide – Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice
- The position of SGLT2 inhibitors in current medical practice – update 2022
- Prediabetes
- Anticoagulation in cancer patients; new recommendations based on randomized clinical trials